Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells

Ko,Kyung-Kon; Lee,Eun-Sang; Joe,Young   Ae; Hong,Yong-Kil

doi:10.3892/etm.2011.207

Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells

Authors:
- Kyung-Kon Ko
- Eun-Sang Lee
- Young Ae Joe
- Yong-Kil Hong
View Affiliations

Affiliations: Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Cancer Research Institute, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
Published online on: January 20, 2011 https://doi.org/10.3892/etm.2011.207
Pages: 343-348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metronomic chemotherapy is a continuous low-dose administration of chemotherapeutic agents to minimize toxicity and target tumor-associated endothelial cells. This therapy is beneficial to anti-angiogenic efficacy which is linked to the inhibition of tumor growth. In the present study, we compared the anti-angiogenicity of temozolomide in human umbilical vein endothelial cells (HUVECs) between conventional and metronomic treatment. Metronomic treatment of temozolomide (TMZ) (6.25 and 12.5 µM) showed increased inhibition of the proliferation of HUVECs compared to an equivalent conventional treatment of TMZ. The differential effects between conventional and metronomic treatment of TMZ were also noted in cell migration and angiogenic tube formation. Notably, the expression level of O6-methylguanine-DNA methyltransferase (MGMT) was markedly reduced in the HUVECs treated with metronomic TMZ (12.5 and 25 µM) compared to cells treated with conventional treatment of TMZ. Accordingly, HUVECs treated with metronomic treatment of TMZ were more sensitive to TMZ treatment. Taken together, metronomic chemotherapy with TMZ enhances the inhibition of angiogenesis accompanied by the down-regulation of MGMT expression in endothelial cells when compared to conventional chemotherapy.

View Figures

View References

1.	Payne MJ, Pratap SE and Middleton MR: Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol. 53:241–252. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev. 4:296–307. 2004. View Article : Google Scholar : PubMed/NCBI
3.	O'Brien V and Brown R: Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis. 27:682–692. 2006.PubMed/NCBI
4.	Roos WP, Batista LF, Naumann SC, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O⁶-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
6.	Antonadou D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 20:3644–3650. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Chua SL, Rosenthal MA, Wong SS, et al: Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncology. 6:38–43. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev. 4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Kim JT, Kim JS, Ko KW, et al: Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 16:33–39. 2006.PubMed/NCBI
10.	Kong DS, Lee JI, Kim WS, et al: A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 16:1117–1121. 2006.PubMed/NCBI
11.	Kurzen H, Schmitt S, Naher H and Mohler T: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs. 14:515–522. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Fukushima T, Takeshima H and Kataoka H: Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 29:4845–4854. 2009.PubMed/NCBI
13.	Natsume A, Ishii D, Wakabayashi T, et al: IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 65:7573–7579. 2005.PubMed/NCBI
14.	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Eng J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Chahal M, Xu Y, Lesniak D, et al: MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncology. 12:822–833. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Tolcher AW, Gerson SL, Denis L, et al: Marked inactivation of O⁶-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 88:1004–1011. 2003.
17.	Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Nat Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
18.	Boiardi A, Silvani A, Ciusani E, et al: Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 0⁶-alkylguanine-DNA alkyltransferase activity. J Neurooncol. 52:149–156. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Pieper RO, Futscher BW, Dong Q and Erickson LC: Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O⁶-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Cancer Res. 51:1581–1585. 1991.PubMed/NCBI
20.	Sanada M, Hidaka M, Takagi Y, et al: Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. Carcinogenesis. 28:2657–2663. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Hirata S, Matsubara T, Saura R, Tateishi H and Hirohata K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32:1065–1073. 1989. View Article : Google Scholar : PubMed/NCBI
22.	Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 2:1843–1849. 1996.PubMed/NCBI
23.	Vacca A, Iurlaro M, Ribatti D, et al: Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 94:4143–4155. 1999.PubMed/NCBI
24.	Fujita K, Sano D, Kimura M, et al: Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep. 18:47–51. 2007.PubMed/NCBI
25.	Lau DH, Duran GE, Lewis AD and Sikic BI: Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer. 70:79–84. 1994. View Article : Google Scholar : PubMed/NCBI
26.	Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW and Boven E: Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 5:2348–2357. 2006. View Article : Google Scholar
27.	Mathieu V, De Neve N, Le Mercier M, et al: Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 10:1383–1392. 2008.PubMed/NCBI
28.	Lam T, Hetherington JW, Greenman J, Little S and Maraveyas A: Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbical venous endothelial cell growth. Acta Oncol. 46:1169–1177. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Park JA, Joe YA, Kim TG and Hong YK: Potentiation of anti-glioma effect with combined temozolomide and interferon-beta. Oncol Rep. 16:1253–1260. 2006.PubMed/NCBI
30.	Citron M, Decker R, Chen S, et al: O⁶-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 51:4131–4134. 1991.
31.	Povey AC, Hall CN, Cooper DP, O'Connor PJ and Margison GP: Determinants of O(6)-alkylguanine-DNA alkyltransferase activity in normal and tumour tissue from human colon and rectum. Int J Cancer. 85:68–72. 2000. View Article : Google Scholar : PubMed/NCBI
32.	Helmlinger G, Endo M, Ferrara N, Hlatky L and Jain RK: Formation of endothelial cell networks. Nature. 405:139–141. 2000. View Article : Google Scholar